
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

